![]() ![]() She also served as Senior Medical Director at SUGEN, Inc. Hannah held the role of Chief Medical Officer for CytomX Therapeutics, overseeing clinical development of conditionally activated protein therapeutics. Hannah has successfully filed over 40 regulatory applications for First-in-Human clinical testing and has played significant roles in the broad marketing approval of multiple anticancer therapeutics. Hannah has served as a consultant to the pharmaceutical and biotechnology industry since 2000, directing the development of investigational cancer therapies. Hannah, M.D., joined us as a director in May 2021. She was a 2011 Philadelphia Business Journal Woman of Distinction winner and a 2015 Pepper Hamilton, LLP remarkable alumna.Īlison L. from Harvard Law School and Bachelor of Arts in politics from Princeton University. She has also served on several nonprofit boards and currently is the Chair of the East Bradford Township Zoning Hearing Board, her local township zoning board. Ali-Jackson currently serves on the board of directors, audit committee, compensation committee, and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly traded clinical stage biopharmaceutical company, as an independent director of Moda Operandi, a privately held online luxury retail company, and as an advisor to life sciences companies and nonprofit organizations. Reddy’s Laboratories Ltd., and Endo Pharmaceuticals, Inc. She has served as legal counsel and as a licensing business executive for a number of pharmaceutical companies, including Merck & Co. a biopharmaceutical assets management company and was legal counsel for the company and its affiliated companies until 2020. Ali-Jackson also co-founded NeXeption, Inc. Ali-Jackson co-founded and successfully transitioned several specialty pharmaceutical and biopharmaceutical companies through multi-million-dollar acquisitions by global pharmaceutical companies. Ali-Jackson built the legal, compliance, and human resources functions at Aclaris. Ali- Jackson is a co-founder of Aclaris Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company, and served as its chief legal officer, chief compliance officer, and corporate secretary since its inception in 2012 until her retirement in January 2022. Kamil Ali-Jackson, Esq., joined us as a director in December 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |